Foresite Capital Management VI LLC Diversified Active

Name: Foresite Capital Management VI LLC Q2 2026 13F Filing | 13F Explorer
Creator: Foresite Capital Management VI LLC
Published: 2026-08-14

Location: West Hollywood, CA

CIK: 0002013341 · Show all filings

Period: Q2 2026 (← Previous)

Filing Date: Aug 14, 2026

Total Value: $643M (100.0% shares, 0.0% debt)

Holdings (23)

CGON CG Oncology, Inc. 26.2%

Value $168M Shares 2,369,574 Est. Cost — Unrealized —

ALMS ALUMIS INC. 18.6%

Value $120M Shares 4,247,670 Est. Cost — Unrealized —

SPTX Seaport Therapeutics, Inc. 6.0%

Value $38.65M Shares 1,779,521 Est. Cost — Unrealized —

DNLI Denali Therapeutics Inc. 5.6%

Value $35.92M Shares 1,396,771 Est. Cost — Unrealized —

CLDX Celldex Therapeutics, Inc. 5.1%

Value $32.73M Shares 879,713 Est. Cost — Unrealized —

AGIO AGIOS PHARMACEUTICALS, INC. 4.5%

Value $29.13M Shares 785,000 Est. Cost — Unrealized —

CRVS Corvus Pharmaceuticals, Inc. 4.3%

Value $27.36M Shares 1,831,233 Est. Cost — Unrealized —

PBLS Parabilis Medicines, Inc. 4.3%

Value $27.34M Shares 999,044 Est. Cost — Unrealized —

GHRS GH Research PLC 3.9%

Value $25.28M Shares 940,493 Est. Cost — Unrealized —

JBIO Jade Biosciences, Inc. 3.1%

Value $19.7M Shares 886,667 Est. Cost — Unrealized —

HNGE Hinge Health, Inc. 2.8%

Value $18.29M Shares 220,400 Est. Cost — Unrealized —

KYMR Kymera Therapeutics, Inc. 2.6%

Value $16.78M Shares 146,332 Est. Cost — Unrealized —

ATAI AtaiBeckley Inc. 2.3%

Value $14.49M Shares 2,750,000 Est. Cost — Unrealized —

VSTM Verastem, Inc. 1.9%

Value $12.02M Shares 3,146,631 Est. Cost — Unrealized —

BEAM Beam Therapeutics Inc. 1.8%

Value $11.33M Shares 330,000 Est. Cost — Unrealized —

NERV Minerva Neurosciences, Inc. 1.7%

Value $11.02M Shares 1,985,584 Est. Cost — Unrealized —

AVBP ArriVent BioPharma, Inc. 1.6%

Value $10.47M Shares 301,341 Est. Cost — Unrealized —

AURA Aura Biosciences, Inc. 1.5%

Value $9.467M Shares 1,333,334 Est. Cost — Unrealized —

CRNX Crinetics Pharmaceuticals, Inc. 1.2%

Value $7.933M Shares 212,010 Est. Cost — Unrealized —

RACC Research Alliance Corp III 0.5%

Value $3.21M Shares 300,000 Est. Cost — Unrealized —

ZURA Zura Bio Ltd 0.4%

Value $2.655M Shares 450,000 Est. Cost — Unrealized —

KLRA Kailera Therapeutics, Inc. 0.1%

Value $826K Shares 37,500 Est. Cost — Unrealized —

IRON Disc Medicine, Inc. 0.0%

Value $70,946 Shares 970 Est. Cost — Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CGON	CG Oncology, Inc.	2,369,574	$168M	26.2%	—	—	COM	156944100
ALMS	ALUMIS INC.	4,247,670	$120M	18.6%	—	—	COM	022307102
SPTX	Seaport Therapeutics, Inc.	1,779,521	$38.65M	6.0%	—	—	COM	81221K108
DNLI	Denali Therapeutics Inc.	1,396,771	$35.92M	5.6%	—	—	COM	24823R105
CLDX	Celldex Therapeutics, Inc.	879,713	$32.73M	5.1%	—	—	COM	15117B202
AGIO	AGIOS PHARMACEUTICALS, INC.	785,000	$29.13M	4.5%	—	—	COM	00847X104
CRVS	Corvus Pharmaceuticals, Inc.	1,831,233	$27.36M	4.3%	—	—	COM	221015100
PBLS	Parabilis Medicines, Inc.	999,044	$27.34M	4.3%	—	—	COM	698955101
GHRS	GH Research PLC	940,493	$25.28M	3.9%	—	—	ORD	G3855L106
JBIO	Jade Biosciences, Inc.	886,667	$19.7M	3.1%	—	—	COM	008064206
HNGE	Hinge Health, Inc.	220,400	$18.29M	2.8%	—	—	CL A	433313103
KYMR	Kymera Therapeutics, Inc.	146,332	$16.78M	2.6%	—	—	COM	501575104
ATAI	AtaiBeckley Inc.	2,750,000	$14.49M	2.3%	—	—	COM	04650F101
VSTM	Verastem, Inc.	3,146,631	$12.02M	1.9%	—	—	COM	92337C203
BEAM	Beam Therapeutics Inc.	330,000	$11.33M	1.8%	—	—	COM	07373V105
NERV	Minerva Neurosciences, Inc.	1,985,584	$11.02M	1.7%	—	—	COM	603380205
AVBP	ArriVent BioPharma, Inc.	301,341	$10.47M	1.6%	—	—	COM	04272N102
AURA	Aura Biosciences, Inc.	1,333,334	$9.467M	1.5%	—	—	COM	05153U107
CRNX	Crinetics Pharmaceuticals, Inc.	212,010	$7.933M	1.2%	—	—	COM	22663K107
RACC	Research Alliance Corp III	300,000	$3.21M	0.5%	—	—	CL A	G75226103
ZURA	Zura Bio Ltd	450,000	$2.655M	0.4%	—	—	CL A	G9TY5A101
KLRA	Kailera Therapeutics, Inc.	37,500	$826K	0.1%	—	—	COM	482931102
IRON	Disc Medicine, Inc.	970	$70,946	0.0%	—	—	COM	254604101